Pharma BD Deal Intelligence
A $1.75B cash-stock-preferred deal that made Watson's international generics push real, not aspirational. Arrow's 20+-country footprint became the launchpad for the 2012 Actavis buy and full Actavis rebrand, with FY2009 net revenue up 10% to $2.8B and no later goodwill impairment on the deal.
Arrow Group was the foundational pivot that turned Watson into a genuine global generics platform, directly enabling the Actavis rebrand and the Actavis/Allergan roll-up era
Full analysis, sources & comparables →Watson goes global with $1.75B Arrow deal, gaining commercial presence in over 20 international markets and a robust pipeline of 40 expected approvals over…
FTC consent order required Watson to divest generic cabergoline to Impax and Arrow's Resolution subsidiary to a new entity to preserve generic competition in…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$1.05B cash + ~$500M Watson stock + $200M zero-coupon preferred. Generics; FTC consent order Dec 2009. Source: Watson IR, BioSpace, BioWorld.
Arrow Group was the foundational pivot that turned Watson into a genuine global generics platform, directly enabling the Actavis rebrand and the Actavis/Allergan roll-up era
Assessment window: 15yr post-close.
The Watson-Arrow transaction was a generics platform deal rather than a single-disease acquisition. Arrow Group marketed more than 100 molecules across 20+ international markets, spanning cardiovascular, CNS, oncology, and primary-care therapy areas with ANDA-equivalent generic formulations.
The 2009 generics landscape was dominated by Teva (post-Barr acquisition), Sandoz (Novartis), and Mylan, with Watson positioned as a sub-scale US player lacking ex-US infrastructure. Arrow's UK Arrow Generics, US/Canada Cobalt Pharmaceuticals, and France Arrow Génériques footprint extended Watson into 20+ countries with ~$647M in 2008 revenue (67% CAGR since 2001), per the merger announcement. Strategic rationale centered on (1) doubling Watson's generics business to $3B+ combined, (2) accessing exclusive US authorized-generic rights to Lipitor (atorvastatin) at November 2011 LOE, and (3) pipeline of 40 expected molecule approvals over three years. The FTC required divestiture of generic cabergoline (Parkinson's, dopamine agonist) to Impax and divestiture of Arrow's Resolution subsidiary (propafenone HCl/fluvastatin) to Reso Holdings to preserve competition. The deal repositioned Watson as a top-five global generics company and was a direct precursor to Watson's 2012 acquisition of Actavis and subsequent rebrand.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Watson Pharmaceuticals (Actavis Inc.) / Arrow Group (this deal) | 2009 | $1.8B | 85 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Watson Pharmaceuticals (Actavis Inc.) / Amarin Development AB (Amarin Corp subsidiary) | 2003 | $150M | 70 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2006 | $1.9B | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Schein Pharmaceutical Inc. | 2000 | $674M | 65 |
| Watson Pharmaceuticals (Actavis Inc.) / Eden Biodesign Limited | 2010 | $15M | 63 |
| Watson Pharmaceuticals (Actavis Inc.) / Andrx Corporation | 2007 | $1.9B | 62 |
← Browse all deals · How we score deals
More: 2009 deals · Watson Pharmaceuticals (Actavis Inc.) deals